Press Releases

12.17.2024

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

12.10.2024

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

11.20.2024

Pfizer Announces New Chief Scientific Officer and President, Research & Development

10.15.2024

Tim Buckley Elected to Pfizer’s Board of Directors

08.27.2024

Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare

07.09.2024

Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development

04.25.2024

Pfizer Announces 2024 Shareholder Meeting Preliminary Results

04.24.2024

Pfizer Declares Second-Quarter 2024 Dividend

04.11.2024

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25

01.30.2024

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance

12.14.2023

Pfizer Completes Acquisition of Seagen

12.12.2023

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen